<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Albireo Pharma, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Albireo Pharma, Inc.

    Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. We were spun out from AstraZeneca in 2008. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Ron Cooper
    • FOUNDED
      2003
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Sarepta Therapeutics, Inc.

    Sarepta Therapeutics, Inc.

    Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused ...

    Sarepta Therapeutics is a U.S. commercial-stage...

    Filing Type:    PU
    Organovo Holdings, Inc.

    Organovo Holdings, Inc.

    Organovo is a biotech platform company that has developed a leadership position wi...

    Organovo is a biotech platform company that has...

    Filing Type:    PU
    Emisphere Technologies, Inc.

    Emisphere Technologies, Inc.

    Emisphere Technologies is a Drug Delivery Company whose core business strategy is ...

    Emisphere Technologies is a Drug Delivery Compa...

    Filing Type:    PU
    CohBar, Inc.

    CohBar, Inc.

    CohBar, Inc. is a leader in the research and development of mitochondria based the...

    CohBar, Inc. is a leader in the research and de...

    Filing Type:    PU
    YiLoLife Inc

    YiLoLife Inc

    YiLo Life uses organic methods and the finest ingredients to create cannabis produ...

    YiLo Life uses organic methods and the finest i...

    Fundraising Status:    EC
    Filing Type:    RA
    Soligenix, Inc.

    Soligenix, Inc.

    Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing an...

    Soligenix, Inc. is a late-stage biopharmaceutic...

    Filing Type:    PU
    GENFIT S.A.

    GENFIT S.A.

    GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and de...

    GENFIT is a late-stage biopharmaceutical compan...

    Filing Type:    PU
    Hepion Pharmaceuticals, Inc.

    Hepion Pharmaceuticals, Inc.

    Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical stage biopharmaceutical compan...

    Hepion Pharmaceuticals (Nasdaq: HEPA) is a clin...

    Filing Type:    PU
    Cara Therapeutics, Inc.

    Cara Therapeutics, Inc.

    Cara Therapeutics is a clinical-stage biopharmaceutical company focused on develop...

    Cara Therapeutics is a clinical-stage biopharma...

    Filing Type:    PU
    Novan, Inc.

    Novan, Inc.

    Novan, Inc. is a clinical development-stage biotechnology company focused on lever...

    Novan, Inc. is a clinical development-stage bio...

    Filing Type:    PU
    Ritter Pharmaceuticals, Inc.

    Ritter Pharmaceuticals, Inc.

    Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the...

    Ritter Pharmaceuticals, Inc. develops novel the...

    Filing Type:    PU
    Redhill Biopharma Ltd.

    Redhill Biopharma Ltd.

    RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a special...

    RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.